Document:

<PAGE>

                                                                    EXHIBIT 10.6

CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTION.

                               BETA TEST AGREEMENT

         This Agreement is made effective as of the 1st day of March, 2001,
between BioNumerik Pharmaceuticals, Inc., with a place of business at 8122
Datapoint Drive, Suite 1250, San Antonio, Texas 78229 ("BioNumerik"), and Cray
Inc., with a place of business at 411 1st Avenue S. Suite 600, Seattle, WA
98104-2860 ("CRAY").

                                    RECITALS:

         WHEREAS BioNumerik and a predecessor of CRAY entered into a Beta Test
Agreement, dated as of August 18, 1994, as amended.

         WHEREAS, BioNumerik and CRAY wish to amend and restate the Beta Test
Agreement to add Cray as a party and provide for the use and evaluation of
computer systems and software and the provision of certain services different
from those described in the original Beta Test Agreement.

         WHEREAS, BioNumerik and CRAY have therefore determined to amend and
restate the Beta Test Agreement with amended terms that will govern the
relationship between the parties with respect to such computer systems, software
and services.

         WHEREAS, this Agreement is a contractual arrangement between CRAY and
BioNumerik in which CRAY will provide BioNumerik with the use of certain CRAY
products for the purposes of testing the products and BioNumerik will provide to
CRAY information and data pertaining to their testing which CRAY may use without
charge to modify, improve or market the products,

         Now, therefore, the parties agree as follows:

1.       Definitions. For purpose of this Agreement, the following words, terms
         and phrases shall have the meanings set forth below:

         1.1      "Beta Test Period" shall mean the period of time described in
                  Section 2.1 during which testing of and adjustments to the
                  products contemplated hereunder will be undertaken.

         1.2      "Equipment" shall mean the computer system products described
                  in Exhibit A to this Agreement, together with any additions,
                  modifications or enhancements thereto provided by CRAY under
                  the terms of this Agreement.

<PAGE>

         1.3      "Software" shall mean the software products described in
                  Exhibit A to this Agreement, together with any additions,
                  modifications or enhancements thereto provided by CRAY under
                  the terms of this Agreement.

         1.4      "Documentation" shall mean the user manuals and other
                  documentation with respect to the Equipment and Software that
                  are provided to BioNumerik during the term of this Agreement.

         1.5      "Products" shall mean Equipment, Software and Documentation.

         1.6      "Principal Contacts" shall mean the individuals designated by
                  the parties to act as principal points of contact regarding
                  matters related to this Agreement.

         1.7      "Confidential Information" shal1 mean the Software, and all
                  other information that is (i) disclosed by either party in any
                  tangible form and clearly labeled or marked as confidential,
                  proprietary or its equivalent, or (ii) disclosed by either
                  party orally or visually, and designated confidential,
                  proprietary or its equivalent at the time of its disclosure
                  and summarized in writing and clearly marked or labeled as
                  confidential, proprietary or its equivalent within thirty (30)
                  days of disclosure.

2.       Beta Test Period and Obligations.

         2.1      Beta Test Period. BioNumerik agrees to act as a beta test site
                  for the Products for the Beta Test Period. The Beta Test
                  Period shall be the term of this Agreement.

         2.2      Beta Test Site. The beta test site shall be the principal
                  offices of BioNumerik located at the address set forth above.

         2.3      Beta Test Obligations. During the Beta Test Period, BioNumerik
                  and CRAY shall each undertake and perform their respective
                  obligations as set forth below.

         2.4      Specifications. BioNumerik shall participate with CRAY in the
                  development of the specifications for the installation and
                  operation of the Products.

         2.5      Testing. During the Beta Test Period BioNumerik agrees to run
                  such test suites and other test programs as may be provided by
                  CRAY. CRAY may request that BioNumerik use special and
                  non-standard operating procedures for the testing of the
                  Products; BioNumerik shall not unreasonably withhold its
                  consent to such a request.

         2.6      Error Notice. BioNumerik's Principal Contact shall notify
                  CRAY's Principal Contact of any material failure, error or
                  other malfunction of any part of the Products.

                                                             BETA TEST AGREEMENT
                                                                          PAGE 2

<PAGE>

         2.7      Access. During the Beta Test Period, BioNumerik will grant
                  CRAY access to the Products and allow CRAY to gain access to
                  the operational data contemplated under this Agreement at such
                  reasonable times as may be required by CRAY for the reasonable
                  purposes of CRAY with respect to the development and sale of
                  their equipment.

                                                             BETA TEST AGREEMENT
                                                                          PAGE 3

<PAGE>

         2.8      Modifications. During the Beta Test Period, BioNumerik's
                  Principal Contact will consult with CRAY 's Principal Contact
                  regarding the performance of the Products and will evaluate
                  the test data and error reports provided by BioNumerik. Should
                  CRAY modify or improve the Products as a result of
                  BioNumerik's testing, CRAY will provide such modification or
                  improvement to BioNumerik at no cost.

         2.9      Use. During the term of this Agreement, CRAY shall loan the
                  Products to BioNumerik. BioNumerik shall use the Products only
                  for the evaluation of the Products under this Agreement and
                  BioNumerik's internal business purposes. Subject to Section
                  12.6, BioNumerik will not offer for sale or otherwise offer or
                  deliver the Products to any third party. BioNumerik will at
                  all times cause the Products to be maintained and operated by
                  qualified personnel in accordance with applicable manuals,
                  will keep the Products in the environment specified in CRAY's
                  Site Planning Manual, and will comply with the requirements of
                  CRAY's insurers which are provided to BioNumerik in writing.
                  CRAY may at any time during normal business hours inspect the
                  Products to ascertain compliance with this Section 2.9. Any
                  equipment which BioNumerik purchases from CRAY during or prior
                  to the period of this agreement, will be wholly owned by
                  BioNumerik and governed only by the term of the purchase
                  contract, but portions of such systems which are not
                  purchased, but provided by CRAY and added to the Products
                  list, will be covered under this agreement.

         2.10     License. CRAY hereby grants a single, non-transferable and
                  non-exclusive license to use the Software during the term of
                  this Agreement. No rights to sublicense or distribute the
                  Software are granted. All rights not specifically granted to
                  BioNumerik by this license shall remain in CRAY. CRAY may
                  include features in the Software which restrict unlicensed use
                  or use of the Software or related data after license
                  expiration. The Software may be used by BioNumerik only on the
                  Equipment or on equipment purchased by BioNumerik from CRAY.
                  BioNumerik shall not modify, clone, reverse assemble, or
                  reverse compile any part of the Software or adopt any part of
                  the Software as its own. BioNumerik shall not translate the
                  Software into a computer language (e.g., FORTRAN or "C")
                  different from the language in which it was provided to
                  BioNumerik by CRAY. BioNumerik is licensed to use only the
                  binary format of the Software unless otherwise agreed in
                  writing by CRAY. The Software is not designed or licensed for
                  use in on-line control equipment in hazardous environments
                  such as operation of nuclear facilities, aircraft navigation
                  or control, life support systems or medical procedures.
                  BioNumerik assumes all risk for any such application and
                  agrees to indemnify CRAY and its suppliers for any and all
                  damages that may be incurred due to the use of Software in
                  such applications. BioNumerik acknowledges that the Software
                  is proprietary and shall remain the property of CRAY or its
                  suppliers. Notwithstanding the foregoing, BioNumerik shall
                  retain all ownership and rights to and may freely use
                  BioNumerik's own proprietary drug design and molecular
                  simulation software and no license is granted to CRAY with
                  respect to such software.

                                                             BETA TEST AGREEMENT
                                                                          PAGE 4

<PAGE>

         2.11     Subject to CRAY 's business priorities and needs, CRAY shall
                  provide reasonable technical assistance to BioNumerik in the
                  use and operation of the Products.

3.       Product Installation. BioNumerik will ensure that the site is
         adequately prepared to receive the Products. CRAY will ship the
         Products at no cost to BioNumerik, install them and run its tests to
         verify proper installation. The Products shall be installed by CRAY at
         the times described in Exhibit B hereto. BioNumerik shal1 cooperate and
         assist with the installation of the Products as reasonably necessary.
         Upon sixty (60) days notice to BioNumerik, CRAY shall also be permitted
         to install any modifications to the Products CRAY deems necessary to
         the proper function of the Products or to achieve the objectives of
         this Agreement. During the term of this Agreement, the parties may
         agree to the installation of other equipment or software that is
         additional to the Equipment or Software, or a modification to the
         Equipment or Software. All such additional equipment or modifications
         shall be deemed Equipment or Software that is subject to the terms of
         this Agreement. In addition to the use of the Products and to
         facilitate BioNumerik's performance of its obligations hereunder,
         during the term of this Agreement CRAY shall grant BioNumerik access to
         the CRAY datacenter systems described in Exhibit A to this Agreement,
         subject to the availability of such systems in CRAY 's datacenter and
         CRAY s business priorities and needs.

4.       Title and Risk of Loss. Title to all Products remains with CRAY.
         BioNumerik shall not sell the Products or encumber their title. CRAY
         assumes all risk of loss of or damage to Products throughout the Beta
         Test Period, except that BioNumerik will be responsible for loss or
         damage caused by negligence of BioNumerik or by environmental factors
         at the installation site.

5.       Obligations of BioNumerik. During the term of this Agreement,
         BioNumerik shall evaluate the Products and provide the results of that
         evaluation to CRAY as services described in Exhibit B to this
         Agreement, and shall provide the other services described in that
         Exhibit B in the times and in the manner described therein.

6.       Principal Contacts. Each party shall designate an individual to act as
         the primary point of contact with the other party with respect to
         issues related to the use of the Products, the obligations of
         BioNumerik and other matters related to this Agreement. The initial
         Principal Contacts are designated in Exhibit D to this Agreement. A
         party may change its Principal Contact by giving notice to the other
         party.

7.       Warranty. THE PRODUCTS PROVIDED TO BIONUMERIK UNDER THIS AGREEMENT ARE
         PROVIDED "AS IS", AND CRAY MAKES NO WARRANTY OF ANY KIND WITH RESPECT
         TO THE PRODUCTS, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF
         MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR FREEDOM FROM
         VIOLATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, WHICH ARE HEREBY
         SPECIFICALLY EXCLUDED.

                                                             BETA TEST AGREEMENT
                                                                          PAGE 5

<PAGE>

8.       Indemnification.

         8.1      Cray shall indemnify BioNumerik and hold BioNumerik harmless
                  from all damages and all reasonable expenditures incurred by
                  BioNumerik as the result of any charge or claim of copyright
                  infringement or violation of proprietary rights asserted
                  against BioNumerik by third parties as a result of
                  BioNumerik's use of the Products hereunder, provided that CRAY
                  is given prompt notice of any such claim and BioNumerik
                  provides reasonable assistance to CRAY in connection with such
                  claims.

         8.2      Should the Products become, or in CRAY's opinion be likely to
                  become, the subject of a claim of infringement of a copyright
                  or violation of proprietary rights of another, CRAY may either
                  (i) procure for BioNumerik the right to continue to use the
                  Products as contemplated hereunder, or (ii) replace or modify
                  the Products to make the use and distribution of the Licensed
                  Products hereunder non-infringing. If neither option is
                  reasonably available to CRAY, this Agreement may be terminated
                  by either party at any time upon written notice subject to the
                  obligation of indemnification set forth above.

         8.3      CRAY shall have no liability for any claim of copyright
                  infringement or violation of proprietary rights to the extent
                  such claim is based on the use of the Products in a manner
                  other than is permitted under this Agreement or is based on a
                  modification of the Products by or for BioNumerik or a third
                  party, or any failure to implement any modification to the
                  Products supplied by CRAY.

         8.4      BioNumerik shall indemnify CRAY and hold CRAY harmless from
                  all damages and all reasonable expenditures incurred by CRAY
                  as the result of any charge or claim asserted against CRAY by
                  third parties resulting from BioNumerik's use of the results
                  of the use of the Products, other than any charge or claim of
                  copyright infringement or violation of proprietary rights, as
                  a result of BioNumerik's use of the Products hereunder,
                  provided that BioNumerik is given prompt notice of any such
                  claim and CRAY provides reasonable assistance to BioNumerik in
                  connection with such claims.

9.       Limitation of Liability.

         9.1      NEITHER PARTY SHALL BE LIABLE FOR ANY LOSS OR DAMAGE CAUSED BY
                  DELAY IN FURNISHING THE PRODUCTS OR SERVICES UNDER THIS
                  AGREEMENT, OR BY DELAY IN ANY OTHER PERFORMANCE UNDER OR
                  PURSUANT TO THIS AGREEMENT.

         9.2      IN NO EVENT WILL EITHER PARTY'S LIABILITY OF ANY KIND INCLUDE
                  ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL LOSSES OR
                  DAMAGES, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH POTENTIAL
                  LOSS OR DAMAGE

                                                             BETA TEST AGREEMENT
                                                                          PAGE 6

<PAGE>

10.      Term and Termination.

         10.1     This Agreement shall take effect as of the date first written
                  above and, unless earlier terminated as provided in Section
                  10.2 below, shall remain in effect for the initial Beta Test
                  Period of three (3) years after March 1, 2001. Thereafter,
                  this Agreement shall be automatically renewed for up to two
                  additional periods of one (1) year each, unless either party
                  shall have given notice to the other of its intention not to
                  renew not later than the date ninety (90) days prior to the
                  beginning of any renewal term of this Agreement.

         10.2     This Agreement may be terminated in accordance with the
                  following provisions:

                  (a)      Either party may terminate this Agreement by giving
                           notice in writing to the other party in the event the
                           other party is in breach of this Agreement and shall
                           have failed to cure such breach within thirty (30)
                           days of receipt of written notice thereof from the
                           first party.

                  (b)      Either party hereto may terminate this Agreement at
                           any time by giving notice in writing to the other
                           party, which notice shall be effective upon dispatch,
                           should the other party file a petition of any type as
                           to its bankruptcy, be declared bankrupt, become
                           insolvent, make an assignment for the benefit of
                           creditors, go into liquidation or receivership, or
                           otherwise lose legal control of its business, or
                           should the other party or a substantial part of its
                           business come under the control of a third party.

                  (c)      CRAY may terminate this Agreement upon sixty (60)
                           days notice if Dr. Hausheer terminates his
                           relationship with BioNumerik.

         10.3     Upon the termination of this Agreement, the parties shall have
                  the following rights and obligations:

                  (a)      The licenses granted to BioNumerik in this Agreement
                           shall terminate immediately, and BioNumerik shall
                           make the Products available to CRAY for
                           deinstallation and return and shall assist CRAY with
                           such deinstallation to the extent reasonably
                           necessary.

                  (b)      Each party shall promptly return to the other all
                           copies then in its possession of Confidential
                           Information provided by the other party.

                  (c)      The provisions of Sections 4, 7, 8, 9 and 11 of this
                           Agreement shall survive.

                                                             BETA TEST AGREEMENT
                                                                          PAGE 7

<PAGE>

11.      Confidentiality.

         11.1     A party receiving Confidential Information shall restrict the
                  use of the Confidential Information to those purposes
                  necessary for the exercise of the receiving party's rights, or
                  performance of the receiving party's obligations under this
                  Agreement. During the term of this Agreement and thereafter,
                  each party shall safeguard against disclosure of the
                  Confidential Information to third parties using the same
                  degree of care to prevent disclosure as it uses to protect its
                  own information of like importance, but at least reasonable
                  care. A party may make only the minimum number of copies of
                  any Confidential Information required to carry out the purpose
                  of this Agreement. All proprietary and copyright notices in
                  the original must be affixed to copies or partial copies.

         11.2     Neither party shall be obligated to maintain any information
                  in confidence or refrain from use if, (i) the information was
                  in the receiving party's possession or was known to it prior
                  to its receipt from the disclosing party, (ii) the information
                  is independently developed by the receiving party without the
                  utilization of Confidential Information of the disclosing
                  party, (iii) the information is or becomes public knowledge
                  without fault of the receiving party, (iv) the information is
                  or becomes available on an a nonconfidential basis to the
                  receiving party from a source other than the disclosing party,
                  (v) the information becomes available on a non-confidential
                  basis to a third party from the disclosing party or from
                  someone acting under its control, or (vi) the information is
                  publicly disclosed (i.e. not under adequate protective order)
                  by the receiving party under an order of a court or government
                  agency, provided that the receiving party provides prior
                  written notification to the disclosing party of such
                  obligation and the opportunity to oppose such order.

12.      General.

         12.1     This Agreement does not make either party the agent or legal
                  representative of the other for any purpose whatsoever.
                  Neither party is granted any right or authority to assume or
                  to create any obligation or responsibility, express or
                  implied, on behalf of or in the name of the other party. In
                  fulfilling its obligations pursuant to this Agreement, each
                  party shall be acting as an independent contractor.

         12.2     Neither party shall have the right to assign or otherwise
                  transfer its rights and obligations under this Agreement
                  except with the prior written consent of the other party. Any
                  prohibited assignment shall be null and void. Notwithstanding
                  the foregoing, subject to the provisions of Section 10.2(b)
                  either party may assign this Agreement without approval to an
                  entity that succeeds to all or substantially all of the
                  party's business or assets (by acquisition, merger or

                                                             BETA TEST AGREEMENT
                                                                          PAGE 8

<PAGE>

                  otherwise), so long as Dr. Frederick Hausheer remains in a
                  similar capacity with BioNumerik, its successors or assigns.

         12.3     Notices permitted or required to be given hereunder shall be
                  deemed sufficient if given by registered or certified mail,
                  postage prepaid, return receipt requested, addressed to the
                  respective addresses of each party as first above written or
                  at such other addresses as the respective parties may
                  designate by like notice from time to time. Notices shal1 be
                  effective upon the earlier to occur of (i) receipt by the
                  party to which notice is given, or (ii) the third (3rd)
                  business day following the date such notice was posted.

         12.4     This Agreement constitutes the entire agreement between the
                  parties with respect to the testing, evaluation and loan of
                  the Products and supersedes all previous agreements by and
                  between the parties related thereto, as well as all proposals,
                  oral or written, and all negotiations, conversations or
                  discussions held between the parties related to this
                  Agreement.

         12.5     This Agreement shall not be deemed or construed to be
                  modified, amended, rescinded or waived, in whole or in part,
                  except by written amendment signed by both parties.

         12.6     The terms of this Agreement are confidential and no party
                  shall issue press releases or engage in other types of
                  publicity of any nature dealing with the commercial and legal
                  details of this Agreement, or any information regarding the
                  performance of the products of the other party, without the
                  other party's prior written approval, which approval shall not
                  be unreasonably withheld. However, approval of such disclosure
                  shall be deemed to have been given to the extent such
                  disclosure is required to comply with governmental rules,
                  regulations or other governmental or legal requirements. In
                  such event, the publishing party shall furnish a copy of such
                  disclosure to the other party. Notwithstanding the foregoing,
                  BioNumerik shall retain the right to (i) demonstrate the
                  Products to third parties in accordance with the performance
                  of its obligations hereunder, and (ii) disclose the existence
                  of this Agreement in its informational material and the
                  material terms of this Agreement to its shareholders and
                  potential shareholders.

         12.7     In the event that any of the terms of this Agreement are in
                  conflict with any rule of law or statutory provision or
                  otherwise unenforceable under the laws or regulations of any
                  government or subdivision thereof, such terms shall be deemed
                  stricken from this Agreement, but such invalidity or
                  unenforceability shall not invalidate any of the other terms
                  of this Agreement and this Agreement shall continue in force,
                  unless the invalidity or unenforceability of any such
                  provisions of this Agreement does substantial violence to, or
                  where the invalid or unenforceable provisions comprise an
                  integral part of, or are otherwise inseparable from, the
                  remainder of this Agreement.

                                                             BETA TEST AGREEMENT
                                                                          PAGE 9

<PAGE>

         12.8     This Agreement may be executed in two or more counterparts and
                  each such counterpart shall be deemed an original of this
                  Agreement.

         12.9     No failure by either party to take any action or assert any
                  right hereunder shall be deemed to be a waiver of such right
                  in the event of the continuation or repetition of the
                  circumstances giving rise to such right.

         12.10    This Agreement shall be governed by, and interpreted and
                  construed in accordance with the laws of the State of
                  Washington.

BIONUMERIK PHARMACEUTICALS, INC.                  CRAY INC.

By: /s/ FREDERICK H. HAUSHEER, M.D.               By: /s/ JIM ROTTSOLK
Name:  Frederick H. Hausheer, M.D.                Name:  Jim Rottsolk

Title: Chief Executive Officer                    Title: Chief Executive Officer

Date:  June 27, 2001                              Date:  June 27, 2001

                                                             BETA TEST AGREEMENT
                                                                         PAGE 10

<PAGE>

                                    EXHIBIT A
                             EQUIPMENT AND SOFTWARE

None.

                                                             BETA TEST AGREEMENT
                                                                         PAGE 11

<PAGE>

                                    EXHIBIT B

                                    PRODUCTS

Software Product
[**]

Cray Datacenter Systems

[**]

For purposes of this agreement, an hour of CPU time is measured as one CPU hour
of [**] time. CPU time on other systems is measured relative to a Cray [**]
based on the theoretical peak performance (the number of CPUs or Processing
Elements (PE's) employed times the theoretical peak performance of a single CPU
or PE) of the other system.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                                             BETA TEST AGREEMENT
                                                                         PAGE 12

<PAGE>

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                                             BETA TEST AGREEMENT
                                                                         PAGE 13

<PAGE>

                                    EXHIBIT C

                    BIONUMERIK EVALUATION AND OTHER SERVICES

I.    Ongoing Obligations

BioNumerik shall provide specific feedback to Cray Inc. with respect to the
appropriateness of their hardware and software for the purpose of computational
drug design. The specifics of the testing will be determined by Barry Bolding of
Cray Inc. but as a minimum will include such metrics as benchmark results for
specific codes on specific applications, scalability (if appropriate) of the
hardware in question, and reliability of the hardware/software environment. Such
test results will NOT be released to anyone other than Cray Inc. without
specific, written approval of Cray Inc.

II.   Annual Obligations

      A. BioNumerik shall send Dr. Hausheer to the annual Cray Inc. Executive
         CUG session each year for informal discussions regarding the use of
         computational methods in drug design. The decision to use Dr. Hausheer
         as an included talk will rest with the Marketing Principal Contact of
         Cray Inc.

      B. BioNumerik shall permit Dr. Hausheer to participate in a yearly
         Symposium sponsored by Cray Inc. The symposia may be in a different
         location each year and it is envisioned that approximately half will be
         overseas. Responsibility for scheduling the Symposia, attracting an
         audience, promoting it within Cray Inc. and coordinating inside the
         organization shall rest with the Technical Point of Contact of Cray
         Inc.

      C. BioNumerik shall participate in an annual review of the progress both
         parties have made against their obligations under the Agreement. The
         Cray Inc. Principal Contact will work with BioNumerik to schedule a
         1-day session at BioNumerik headquarters to review the Agreement and
         the progress made.

III.  Additional Obligations

      A. BioNumerik shall prepare and endeavor to publish papers for each of the
         drugs developed using computational methods. The papers will be
         published in journals that qualify as "scholarly" and require peer
         review as part of the publication process. The publications should take
         place as soon as possible but should not occur before BioNumerik has
         taken sufficient measures to protect itself through the appropriate
         patent process.

      B. With sufficient notice, BioNumerik shall send Dr. Hausheer to Seattle,
         WA and/or Eagan MN to meet with selected customers for the purpose of
         discussing computational methods in drug design. Alternatively, the
         meetings may take place at  the customers' place of business. The
         decision as to the results of the specific customer visit will rest
         with the Technical Point of Contact of Cray Inc.

      C. With sufficient notice, BioNumerik shall host selected customers at
         their location for the purpose of discussing computational methods in
         drug design. The decision as to the results of the specific customer
         visit will rest with the Technical Point of Contact of Cray Inc.

      D. BioNumerik shall provide a presentation (e.g. PowerPoint) of at least
         one computational chemistry drug design "success story" which may be
         shown to selected customers with the purpose of discussing
         computational methods used in drug design. It is envisioned that at
         least one additional presentation will be made available to the
         Technical Point of Contact of Cray Inc. during each year of the term of
         this agreement.

      E. BioNumerik shall endeavor to help Cray Inc. define the "value
         proposition" offered by Cray Inc. products within the pharmaceutical
         industry. Through discussion, email or other interactions, Dr. Hausheer
         will interact with the Marketing Point of Contact of Cray Inc. to
         clarify the added value which Cray Inc. products offer this industry.

                                                             BETA TEST AGREEMENT
                                                                         PAGE 14

<PAGE>

                                                             BETA TEST AGREEMENT
                                                                         PAGE 15

<PAGE>

                                    EXHIBIT D

                               PRINCIPAL CONTACTS

The BioNumerik Principal Contact shall be Dr. Fred H. Hausheer; and Dr. Jeffrey
Saxe and Dr. P. Seetharamulu shall act as alternate Principal Contacts.

The Cray Inc. Principal Contact shall be:

1.    With respect to the technical aspects of the relationship established in
      this Agreement, Eric Pitcher or his subsequent designee.

2.    With respect to marketing aspects of the relationship established in this
      Agreement, Eric Pitcher or his subsequent designee.

3.    With respect to the general terms of the relationship established in this
      Agreement, Eric Pitcher.

Cray Inc. shall reimburse BioNumerik for all reasonable out-of-pocket expenses
of the BioNumerik Principal Contact in satisfying BioNumerik's obligations under
this Agreement, including, but not limited to travel, lodging, meals, and a
negotiated per diem. All services provided by the BioNumerik Point of Contact
under this Agreement will be subject to the obligations of the BioNumerik Point
of Contact to BioNumerik, and Cray Inc. will cooperate with the BioNumerik Point
of Contact to avoid any interference with the operation of BioNumerik.

                                                             BETA TEST AGREEMENT
                                                                         PAGE 16<PAGE>
                                                                   EXHIBIT 10.10

                        BIONUMERIK PHARMACEUTICALS, INC.

                         1995 DIRECTOR STOCK OPTION PLAN

         1. Purposes of the Plan. The purposes of this Director Stock Option
Plan are to attract and retain the best available personnel for service as
Directors of the Company, to provide additional incentive to the Outside
Directors of the Company to serve as Directors, and to encourage their continued
service on the Board.

                  All options granted hereunder shall be "non-statutory stock
options".

         2. Definitions. As used herein, the following definitions shall apply:

                  (a)      "Board" shall mean the Board of Directors of the
                           Company.

                  (b)      "Common Stock" shall mean the Common Stock of the
                           Company.

                  (c)      "Company" shall mean BIONUMERIK PHARMACEUTICALS,
                           INC., a Texas corporation.

                  (d)      "Continuous Status as a Director" shall mean the
                           absence of any interruption or termination of status
                           as a Director.

                  (e)      "Director" shall mean a member of the Board.

                  (f)      "Employee" shall mean any person, including officers
                           and Directors, employed by the Company or any Parent
                           or Subsidiary of the Company. The payment of a
                           director's fee by the Company shall not be sufficient
                           in and of itself to constitute "employment" by the
                           Company.

                  (g)      "Exchange Act" shall mean the Securities Exchange Act
                           of 1934, as amended.

                  (h)      "Option" shall mean a stock option granted pursuant
                           to the Plan.

                  (i)      "Optioned Stock" shall mean the Common Stock subject
                           to an Option.

                  (j)      "Optionee" shall mean an Outside Director who
                           receives an Option.

                  (k)      "Outside Director" shall mean a Director who is not
                           an Employee.

<PAGE>
                  (l)      "Parent" shall mean a "parent corporation", whether
                           now or hereafter existing, as defined in Section
                           425(e) of the Internal Revenue Code of 1986, as
                           amended.

                  (m)      "Plan" shall mean this 1995 Director Stock Option
                           Plan, as amended.

                  (n)      "Share" shall mean a share of the Common Stock, as
                           adjusted in accordance with Section 11 of the Plan.

                  (o)      "Subsidiary" shall mean a "subsidiary corporation",
                           whether now or hereafter existing, as defined in
                           Section 425(f) of the Internal Revenue Code of 1986,
                           as amended.

         3. Stock Subject to the Plan. Subject to the provisions of Section 11
of the Plan, the maximum aggregate number of Shares which may be optioned and
sold under the Plan is 300,000 Shares (the "Pool") of Common Stock. The Shares
may be authorized, but unissued, or reacquired Common Stock.

         If an Option should expire or become unexercisable for any reason
without having been exercised in full, the unpurchased Shares which were subject
thereto shall, unless the Plan shall have been terminated, become available for
future grant under the Plan.

         4. Administration of and Grants of Options under the Plan.

                  (a)      Administrator. Except as otherwise required herein,
                           the Plan shall be administered by the Board.

                  (b)      Procedure for Grants. All grants of Options hereunder
                           shall be made strictly in accordance with the
                           following provisions:

                           (i) No person shall have any discretion to select
which Outside Directors shall be granted Options.

                           (ii) Each Outside Director shall be automatically
granted an Option (the "First Option") to purchase the First Option Amount (as
described in Section 4(b)(vi) below) upon the later to occur of (A) the
effective date of this Plan, as determined in accordance with Section 6 hereof,
or (B) the date on which such person first becomes a Director, whether through
election by the shareholders of the Company or appointment by the Board of
Directors to fill a vacancy.

                           (iii) After a First Option has been granted to any
Outside Director, each Outside Director shall thereafter be automatically
granted an Option (a "Subsequent Option") to purchase the Subsequent Option
Amount (as described in Section 4(b)(vii) below) on the day of each subsequent
annual shareholders meeting at which such Outside Director is reelected to an
additional term; provided, however, that for the first annual shareholders
meeting following the date on which such person first becomes a Director (the
"First Subsequent Meeting Date"), such

                                       2
<PAGE>
Outside Director shall be granted an Option to purchase a number of Shares which
is equal to the Subsequent Option Amount for other Directors at such First
Subsequent Meeting Date multiplied by that fraction of a year (which fraction
shall not exceed one) that has elapsed from the date such person first became a
Director to such First Subsequent Meeting Date.

                           (iv) Notwithstanding the provisions of subsections
(ii) and (iii) hereof, in the event that a grant would cause the number of
Shares subject to outstanding Options plus the number of Shares previously
purchased upon exercise of Options to exceed the Pool, then each such automatic
grant shall be for that number of Shares determined by dividing the total number
of Shares remaining available for grant by the number of Outside Directors on
the automatic grant date. Any further grants shall then be deferred until such
time, if any, as additional Shares become available for grant under the Plan
through action to increase the number of Shares which may be issued under the
Plan or through cancellation or expiration of Options previously granted
hereunder.

                           (v) The terms of an Option granted hereunder shall be
consistent with the requirements set forth elsewhere in this plan and shall
additionally include the following:

                           (A) The Option shall be exercisable only while the
Outside Director remains a Director of the Company, except as set forth in
Section 9 hereof.

                           (B) With respect to grants occurring prior to June 1,
1999, the Option shall become exercisable in installments cumulatively with
respect to 1/36 of the Shares covered thereby for each complete calendar month
after the date of grant of such Option provided, however, that in no event shall
any Option be exercisable prior to obtaining shareholder approval of the Plan in
accordance with Section 17 hereof. With respect to grants occurring after June
1, 1999, the Option shall become exercisable in installments cumulatively with
respect to 1/12 of the Shares covered thereby for each complete calendar month
after the date of grant of such Option.

                           (C) Notwithstanding any other provisions hereof, the
grant of initial Options to the Outside Directors of the Company holding office
on the date the Plan is adopted by the Board shall be subject to shareholder
approval of the Plan in accordance with Section 17(a) hereof and, subject to
such approval, the monthly vesting of such initial Options shall commence as of
the effective date of the Plan.

                           (vi) With respect to grants occurring prior to June
1, 1999, the "First Option Amount" shall be an Option to purchase 7,500 Shares.
With respect to grants occurring after June 1, 1999, the "First Option Amount"
shall be an Option to purchase the Industry Report Amount as determined in
accordance with Section 4(b)(vii) below.

                           (vii) With respect to grants occurring prior to June
1, 1999, the "Subsequent Option Amount" shall be an Option to purchase 2,500
Shares. With respect to grants occurring after June 1, 1999, the "Subsequent
Option Amount" shall be an Option to purchase that number of Shares (the
"Industry Report Amount") that is determined by the Board in good faith to
correspond to the size of option grant awards made to outside directors upon

                                       3
<PAGE>
reelection to the board as published in current and representative report(s)
(collectively, the "Industry Report") of industry specific compensation amounts
determined in good faith by the Board to be representative benchmarks of outside
director compensation for companies in the life science industry. Option award
amounts in the Industry Report based on a standardized number of outstanding
shares shall be proportionately adjusted to reflect the actual number of
outstanding shares of Company stock at the time of the grant.

                  (c) Powers of the Board. Subject to the provisions and
restrictions of the Plan, the Board shall have the authority, in its discretion:
(i) to determine, upon review of relevant information and in accordance with
Section 8(b) of the Plan, the fair market value of the Common Stock; (ii) to
determine the exercise price per share of Options to be granted, which exercise
price shall be determined in accordance with Section 8(a) of the Plan; (iii) to
interpret the Plan; (iv) to prescribe, amend and rescind rules and regulations
relating to the Plan; (v) to authorize any person to execute on behalf of the
Company any instrument required to effectuate the grant of an Option previously
granted hereunder; and (vi) to make all other determinations (including the
determinations provided in Section 4(b) hereof) deemed necessary or advisable
for the administration of the Plan.

                  (d) Effect of Board's Decision. All decisions, determinations
and interpretations of the Board shall be final and binding on all Optionees and
any other holders of any Options granted under the Plan.

                  (e) Suspension or Termination of Option. If the Chief
Executive Officer or his designee reasonably believes that an Optionee has
committed an act of misconduct, the Chief Executive Officer may suspend the
Optionee's right to exercise any option pending a determination by the Board of
Directors (excluding the Outside Director accused of such misconduct). If the
Board of Directors (excluding the Outside Director accused of such misconduct)
determines an Optionee has committed an act of embezzlement, fraud, dishonesty,
nonpayment of an obligation owed to the Company, breach of fiduciary duty or
deliberate disregard of the Company rules resulting in loss, damage or injury to
the Company, or if an Optionee makes an unauthorized disclosure of any Company
trade secret or confidential information, engages in any conduct constituting
unfair competition, induces any Company customer to breach a contract with the
Company or induces any principal for whom the Company acts as agent to terminate
such agency relationship, neither the Optionee nor his estate shall be entitled
to exercise any option whatsoever. In making such determination, the Board of
Directors (excluding the Outside Director accused of such misconduct) shall act
fairly and shall give the Optionee an opportunity to appear and present evidence
on Optionee's behalf at a hearing before a committee of the Board.

         5. Eligibility. Options may be granted only to Outside Directors. All
Options shall be automatically granted in accordance with the terms set forth in
Section 4(b) hereof. An Outside Director who has been granted an Option may, if
he is otherwise eligible, be granted an additional Option or Options in
accordance with such provisions.

                       The Plan shall not confer upon any Optionee any right
       with respect to continuation of service as a Director or nomination to
       serve as a Director, nor shall it interfere in

                                       4
<PAGE>
any way with any rights which the Director or the Company may have to terminate
his directorship at any time.

         6. Term of Plan. The Plan shall become effective upon the earlier to
occur of its adoption by the Board of Directors of the Company or its approval
by the shareholders of the Company as described in Section 17 of the Plan. It
shall continue in effect for a term of ten (10) years unless sooner terminated
under Section 13 of the Plan.

         7. Term of Option. The term of each Option shall be ten (10) years from
the date of grant thereof.

         8. Exercise Price and Consideration.

                  (a) Exercise Price. The exercise price per Share of the First
Options to be granted to the Outside Directors of the Company holding office on
the date of adoption of the Plan by the Board shall be $4.10 per Share.
Thereafter, the per Share exercise price for the Shares to be issued pursuant to
exercise of an Option shall be 100% of the fair market value per Share on the
date of grant of the Option.

                  (b) Fair Market Value. The fair market value shall be
determined by the Board in its discretion; provided, however, that where there
is a public market for the Common Stock, the fair market value per Share shall
be the mean of the bid and asked prices of the Common Stock in the over-the
counter market on the date of grant, as reported in The Wall Street Journal (or,
if not so reported, as otherwise reported by the National Association of
Securities Dealers Automated Quotation ("NASDAQ") System) or, in the event the
Common Stock is traded on the NASDAQ National Market System or listed on a stock
exchange, the fair market value per Share shall be the closing price on such
system or exchange on the date of grant of the Option, as reported in The Wall
Street Journal.

                  (c) Form of Consideration. The consideration to be paid for
the Shares to be issued upon exercise of an Option shall consist entirely of
cash, check, other Shares of Common Stock of the Company which (i) either have
been owned by the Optionee for more than six (6) months on the date of
surrender, or were not acquired directly or indirectly from the Company, and
(ii) have a fair market value on the date of surrender equal to the aggregate
exercise price of the Shares as to which said Option shall be exercised, or any
combination of such methods of payment.

         9. Exercise of Option.

                  (a) Procedure for Exercise: Rights as a Shareholder. Any
Option granted hereunder shall be exercisable at such times as are set forth in
Section 4 hereof; provided, however, that no Options shall be exercisable until
shareholder approval of the Plan in accordance with Section 17 hereof has been
obtained.

                  An Option may not be exercised for a fraction of a Share.

                                       5
<PAGE>
                 An Option shall be deemed to be exercised when written notice
of such exercise has been given to the Company in accordance with the terms of
the Option by the person entitled to exercise the Option and full payment for
the Shares with respect to which the Option is exercised has been received by
the Company. Full payment may consist of any consideration and method of payment
allowable under Section 8(c) of the Plan. Until the issuance (as evidenced by
the appropriate entry on the books of the Company or of a duly authorized
transfer agent of the Company) of the stock certificate evidencing such Shares,
no right to vote or receive dividends or any other rights as a shareholder shall
exist with respect to the Optioned Stock, notwithstanding the exercise of the
Option. A share certificate for the number of Shares so acquired shall be issued
to the Optionee as soon as practicable after exercise of the Option. No
adjustment will be made for a dividend or other right for which the record date
is prior to the date the stock certificate is issued, except as provided in
Section 11 of the Plan.

                  Exercise of an Option in any manner shall result in a decrease
in the number of Shares which thereafter may be available, both for purposes of
the Plan and for sale under the Option, by the number of Shares as to which the
Option is exercised.

                  (b) Termination of Status as a Director. In the event of the
termination of the Outside Director's Continuous Status as a Director, he may,
but only within thirty (30) days after the date of such termination, exercise
his Option to the extent that he was entitled to exercise it at the date of such
termination. To the extent that he was not entitled to exercise an Option at the
date of such termination, or if he does not exercise such Option (which he was
entitled to exercise) within the time specified herein, the Option shall
terminate.

                  (c) Disability of Optionee. Notwithstanding the provisions of
Section 9(b) above, in the event of termination of an Optionee's Continuous
Status as a Director as a result of his total and permanent disability (as
defined in Section 22(e)(3) of the Internal Revenue Code of 1986, as amended),
he may, but only within six (6) months (or such other period of time not
exceeding twelve (12) months as is determined by the Board) from the date of
such termination (but in no event later than the date of expiration of the term
of such Option as set forth in the Option Agreement), exercise his Option to the
extent he was entitled to exercise it at the date of such termination. To the
extent that he was not entitled to exercise the Option at the date of
termination, or if he does not exercise such Option (which he was entitled to
exercise) within the time specified herein, the Option shall terminate.

                  (d) Death of Optionee. In the event of the death of an
Optionee:

                           (i) during the term of the Option who is at the time
of his death a Director of the Company and who shall have been in Continuous
Status as a Director since the date of grant of the Option, the Option may be
exercised, at any time within twelve (12) months following the date of death, by
the Optionee's estate or by a person who acquired the right to exercise the
Option by bequest or inheritance, but only to the extent of the right to
exercise that had accrued at the date of death.

                           (ii) within thirty (30) days after the termination of
Continuous Status as a Director, the Option may be exercised, at any time within
twelve (12) months following the

                                       6
<PAGE>
date of death, by the Optionee's estate or by a person who acquired the right to
exercise the Option by bequest or inheritance, but only to the extent of the
right to exercise that had accrued at the date of termination.

          10. Non-Transferability of Options. Unless determined otherwise by the
Board, an Option may not be sold, pledged, assigned, hypothecated, transferred
or disposed of in any manner other than by will or by the laws of descent or
distribution or pursuant to a qualified domestic relations order as defined by
the Code or Title I of the Employee Retirement Income Security Act, or the rules
thereunder. The designation of a beneficiary by an Optionee does not constitute
a transfer. Unless determined otherwise by the Board, an Option may be
exercised, during the lifetime of the Optionee, only by the Optionee or a
transferee permitted by this Section 10. If the Board makes an Option
transferable, such Option shall contain such additional terms and conditions as
the Board deems appropriate.

          11. Adjustments Upon Changes in Capitalization or Merger. Subject to
any required action by the shareholders of the Company, the number of shares of
Common Stock covered by each outstanding Option, and the number of shares of
Common Stock which have been authorized for issuance under the Plan but as to
which no Options have yet been granted or which have been returned to the Plan
upon cancellation or expiration of an Option, as well as the price per share of
Common Stock covered by each such outstanding Option, shall be proportionately
adjusted for any increase or decrease in the number of issued shares of Common
Stock resulting from a stock split, reverse stock split, stock dividend,
combination or reclassification of the Common Stock, or any other increase or
decrease in the number of issued shares of Common Stock effected without payment
or receipt of consideration by the Company; provided, however, that conversion
of any convertible securities of the Company shall not be deemed to have been
"effected without receipt of consideration." Such adjustment shall be made by
the Board, whose determination in that respect shall be final, binding and
conclusive. Except as expressly provided herein, no issuance by the Company of
shares of stock of any class, or securities convertible into shares of stock of
any class, shall affect, and no adjustment by reason thereof shall be made with
respect to, the number or price of shares of Common Stock subject to an Option.

         In the event of the proposed dissolution or liquidation of the Company,
the Board shall notify the Optionee at least fifteen (15) days prior to such
proposed action. To the extent it has not been previously exercised, the Option
will terminate immediately prior to the consummation of such proposed action. In
the event of a merger of the Company with or into another corporation in which
the stock of the Company is exchanged for stock of another company, the Option
shall be assumed or an equivalent option shall be substituted by such successor
corporation or a parent or subsidiary of such successor corporation, unless the
Board determines, in the exercise of its sole discretion and in lieu of such
assumption or substitution, that the Optionee shall have the right to exercise
the Option as to all of the Optioned Stock, including Shares as to which the
Option would not otherwise be exercisable. If the Board makes an Option fully
exercisable in lieu of assumption or substitution in the event of a merger, the
Board shall notify the Optionee that the Option shall be fully exercisable for a
period of fifteen (15) days from the date of such notice, and the Option will
terminate upon the expiration of such period.

                                       7
<PAGE>
          12. Time of Granting Options. The date of grant of an Option shall,
for all purposes, be the date determined in accordance with Section 4(b) hereof.
Notice of the determination shall be given to each Outside Director to whom an
Option is so granted within a reasonable time after the date of such grant.

          13. Amendment and Termination of the Plan.

                  (a) Amendment and Termination. The Board may at any time
amend, alter, suspend or discontinue the Plan, but no amendment, alteration,
suspension or discontinuation shall be made which would impair the rights of any
Optionee under any grant theretofore made, without his or her consent. In
addition, to the extent necessary and desirable to comply with Rule 16b-3 under
the Exchange Act (or any other applicable law or regulation, including the
requirements of the NASD or an established stock exchange), the Company shall
obtain shareholder approval of any Plan amendment in such a manner and to such a
degree as required. Notwithstanding the foregoing, the provisions set forth in
Section 4(b) of this Plan (and any other Sections of this Plan that affect the
formula award terms required to be specified in this Plan by Rule 16b-3) shall
not be amended more than once every six months, other than to comport with
change in the Code, the Employee Retirement Income Security Act, or the rules
thereunder.

                  (b) Effect of Amendment or Termination. Any such amendment or
termination of the Plan shall not affect Options already granted and such
Options shall remain in full force and effect as if this Plan had not been
amended or terminated, unless mutually agreed otherwise between the Optionee and
the Board, which agreement must be in writing and signed by the Optionee and the
Company.

          14. Conditions Upon Issuance of Shares. Shares shall not be issued
pursuant to the exercise of an Option unless the exercise of such Option and the
issuance and delivery of such Shares pursuant thereto shall comply with all
relevant provisions of law, including, without limitation, the Securities Act of
1933, as amended, the Exchange Act, the rules and regulations promulgated
thereunder, state securities laws, and the requirements of any stock exchange
upon which the Shares may then be listed, and shall be further subject to the
approval of counsel for the Company with respect to such compliance.

                   As a condition to the exercise of an Option, the Company may
require the person exercising such Option to represent and warrant at the time
of any such exercise that the Shares are being purchased only for investment and
without any present intention to sell or distribute such Shares, if, in the
opinion of counsel for the Company, such a representation is required by any of
the aforementioned relevant provisions of law.

                   Inability of the Company to obtain authority from any
regulatory body having jurisdiction, which authority is deemed by the Company's
counsel to be necessary to the lawful issuance and sale of any Shares hereunder,
shall relieve the Company of any liability in respect of the failure to issue or
sell such Shares as to which such requisite authority shall not have been
obtained.

                                       8
<PAGE>
         15. Reservation of Shares. The Company, during the term of this Plan,
will at all times reserve and keep available such number of Shares as shall be
sufficient to satisfy the requirements of the Plan.

         16. Option Agreement. Options shall be evidenced by written option
agreements in such form as the Board shall approve.

         17. Shareholder Approval.

                  (a) Continuance of the Plan shall be subject to approval by
the shareholders of the Company at or prior to the first annual meeting of
shareholders held subsequent to the adoption of the Plan by the Board of
Directors of the Company. If such shareholder approval is obtained at a duly
held shareholders' meeting, it may be obtained by the affirmative vote of the
holders of a majority of the outstanding shares of the Company present or
represented and entitled to vote thereon. If such shareholder approval is
obtained by written consent, it may be obtained by the written consent of the
holders of a majority of the outstanding shares of the Company.

                  (b) At such time as the Company is subject to Section 14(a) of
the Exchange Act, any required approval of the shareholders of the Company shall
be solicited substantially in accordance with the applicable provisions of
Section 14(a) of the Exchange Act and the rules and regulations promulgated
thereunder.

          18. Information to Optionees. The Company shall provide to each
Optionee, during the period for which such Optionee has one or more Options
outstanding, copies of all annual reports to shareholders, proxy statements and
other information provided to all shareholders of the Company.

                                       9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}]]